谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Alanine Aminotransferase (ALT) ,etc. by FLIA (Flow Luminescence Immunoassay)
GPT; ALAT; SGPT; AAT1; GPT1; Serum Glutamic Pyruvic Transaminase; Alanine Transaminase; Glutamate pyruvate transaminase 1; Glutamic--alanine transaminase 1
（注：單次混測多因子不超過8個指標 ）
- 編號ULMA207Rb
- 物種Oryctolagus cuniculus (Rabbit，兔) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.02-20ng/mL
- 靈敏度最小可檢測劑量小于等于0.007 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 1281 ¥ 1330 ¥ 1404 ¥ 1502 ¥ 1601 ¥ 1749 ¥ 1970 ¥ 2463 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 92-101 | 96 |
| EDTA plasma(n=5) | 84-105 | 91 |
| heparin plasma(n=5) | 95-102 | 98 |
| sodium citrate plasma(n=5) | 80-91 | 83 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 97-105% | 94-102% | 91-102% | 98-105% |
| EDTA plasma(n=5) | 78-99% | 96-105% | 78-102% | 95-103% |
| heparin plasma(n=5) | 95-104% | 94-103% | 96-105% | 89-98% |
| sodium citrate plasma(n=5) | 96-103% | 87-103% | 91-101% | 80-104% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Oryctolagus cuniculus (Rabbit，兔) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| USEA207Rb | 谷丙轉(zhuǎn)氨酶(ALT)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA207Rb | 谷丙轉(zhuǎn)氨酶(ALT)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Cancer Gene Therapy | Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells [Nature: 201067] |
| Endocrinology. | Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. [PubMed: 23093702] |
| Kidney International | Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms [PubMed: PMC3612362] |
| Proceedings of the National Academy of Sciences | Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model [PubMed: PMC3382536] |
| African Journal of Pharmacy and Pharmacology | Protective effect of Panax ginseng against N-acetyl-p-aminophenol-induced hepatotoxicity in rats [Academicjournals: Source] |
| Kidney International | Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and-independent mechanisms [Pubmed: 23325074] |
| European Journal of Pharmacology | Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats [ScienceDirect: S0014299914000235] |
| Eur J Nutr. | Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis [Pubmed:25657013] |
| Experimental and Molecular Pathology | Resolvin E1 and chemerin C15 peptide do not improve rodent non-alcoholic steatohepatitis [Pubmed:25681756] |
| Gastroenterol Res Pract | Assessing the Effect of Leptin on Liver Damage in Case of Hepatic Injury Associated with Paracetamol Poisoning [PubMed: 26697061] |
| FNG & Bilim T?p Dergisi | The effects of subacute deltamethrin exposure on rat liver: histochemical, immunohistochemical, and biochemical study [xmlui:11446] |
| Gastroenterol Res Pract. | Advanced Studies in Clinical and Experimental Research in Gastroenterology [Pubmed:26955389] |
| DARU?Journal of Pharmaceutical Sciences | Effects of developmental exposure to silver in ionic and nanoparticle form: A study in rats [pubmed:27716437] |
| Oncotarget | Dihydromyricetin?protects?against?liver?ischemia/reperfusion?induced?apoptosis?via?activation?ofFOXO3a-mediated?autophagy. [pubmed:27793014] |
| Scientific Reports | Adiponectin?protects?the?rats?liver?against?chronic?intermittent?hypoxia?induced?injury?throughAMP-activated?protein?kinase?pathway. [pubmed:27678302] |
| ?Biochimica et Biophysica Acta (BBA)-General Subjects | Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats [pubmed:28341485] |
| Gastroenterology Research and Practice | Antifibrotic Effect of Lactulose on a Methotrexate-Induced Liver Injury Model [pubmed:28912805] |
| PLoS Pathogens | Alcohol-associated intestinal dysbiosis impairs pulmonary host defense against Klebsiella pneumoniae. [pubmed:28604843] |
| FEBS?Open?Bio | A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis [Pubmed:29321963] |
| Rolle von CMKLR1 und dessen Liganden bei der nicht-alkoholischen Fettlebererkrankung [Regensburg:Source] | |
| Cumhuriyet Medical Journal | The valuable effects of potent antioxidant curcumin in cisplatin induced liver and kidney injury [DOI:Source] |
| BMC?Complementary and Alternative?Medicine? | Hepatoprotective activity of Erythrina× neillii leaf extract and characterization of its phytoconstituents [Pubmed: 28095910] |
| Scientific Reports | Brg1 promotes liver regeneration after partial hepatectomy via regulation of cell cycle [Pubmed: 30787318] |
| Brain Behavior and Immunity | Corticosterone-mediated microglia activation affects dendritic spine plasticity and motor learning functions in minimal hepatic encephalopathy [Pubmed: 31437533] |
| Biomed Research International | Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet [Pubmed: 32149099] |
| Frontiers in Immunology | CD47 Deficiency in Mice Exacerbates Chronic Fatty Diet-Induced Steatohepatitis Through Its Role in Regulating Hepatic Inflammation and Lipid Metabolism [Pubmed: 32158445] |
| Nanomaterials | Biological Safety and Biodistribution of Chitosan Nanoparticles [Pubmed: 32340313] |
| European Journal of Biology | Effects of Tempol in Lipopolysaccharide-Induced Liver Injury [] |
| Pathogens | Antimalarial Effect of the Total Glycosides of the Medicinal Plant, Ranunculus japonicus [33925018] |
| Gastroenterol Res Pract | An Experimental Study: Benefits of Digoxin on Hepatotoxicity Induced by Methotrexate Treatment [34804155] |
| Int Immunopharmacol | Taraxasterol mitigates Con A-induced hepatitis in mice by suppressing interleukin-2 expression and its signaling in T lymphocytes [34848154] |
| J Magn Reson Imaging | Water Specific MRI T1 Mapping for Evaluating Liver Inflammation Activity Grades in Rats With Methionine‐Choline‐Deficient Diet‐Induced Nonalcoholic Fatty Liver?… [Pubmed:35212074] |
| Medcomm | Blockade of mIL‐6R alleviated lipopolysaccharide‐induced systemic inflammatory response syndrome by suppressing NF‐κB‐mediated Ccl2 expression and?… [Pubmed:35548710] |
| International Immunopharmacology | Dimethyl fumarate ameliorates autoimmune hepatitis in mice by blocking NLRP3 inflammasome activation [Pubmed:35605433] |
